Azurity Pharmaceuticals Acquires Sebela's Bowel Prep Franchise

SERB Pharmaceuticals Acquires Y-mAbs Therapeutics

September 16, 2025

Biotechnology

SERB Pharmaceuticals completed its acquisition of Y-mAbs Therapeutics following a tender offer and statutory merger, making Y-mAbs a wholly owned subsidiary and delisting it from Nasdaq. The deal adds Y-mAbs' antibody-based oncology assets — including Danyelza (naxitamab-gqgk) — to SERB's rare disease and rare oncology portfolio to expand its commercial capabilities in pediatric and rare cancers.

Laboratoires SERB (Charterhouse-backed) to acquire BTG Specialty Pharmaceuticals from Boston Scientific

December 1, 2020

Pharmaceuticals

Charterhouse Capital Partners–backed Laboratoires SERB has agreed to acquire BTG Specialty Pharmaceuticals from Boston Scientific. The deal expands SERB’s portfolio of emergency and critical‑care medicines (including CroFab, DigiFab and Voraxaze), strengthening its manufacturing capabilities and global commercial reach.

Ipsen Acquires Albireo Pharma

January 9, 2023

Biotechnology

Ipsen has agreed to acquire Albireo Pharma in a cash tender offer of $42.00 per share plus a contingent value right (CVR) tied to FDA approval in biliary atresia, in a transaction intended to expand Ipsen's Rare Disease portfolio. The acquisition brings Albireo's approved pediatric liver drug Bylvay (odevixibat) and a pipeline of bile-acid modulators into Ipsen's global R&D and commercial capabilities.

Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

September 24, 2021

Pharmaceuticals

Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.

Teleflex Acquires Palette Life Sciences

October 10, 2023

Medical Devices

Teleflex Incorporated completed its acquisition of Palette Life Sciences AB for $600 million in upfront cash plus up to $50 million in potential milestone payments. The deal adds Palette’s NASHA-based products — including the Barrigel rectal spacer, Deflux and Solesta — to Teleflex’s interventional urology portfolio; Palette’s standalone net revenue was expected to be about $56 million for 2023.

Azurity Pharmaceuticals Acquires Slayback Pharma

September 27, 2023

Pharmaceuticals

Azurity Pharmaceuticals has completed the acquisition of Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making Slayback a wholly owned subsidiary of Azurity. The deal expands Azurity's R&D and complex formulation capabilities and accelerates its pipeline for new medicine launches as part of its growth strategy under majority owner QHP Capital.